Programmes Opioids Clinical Primer Ressources Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Certains contenus peuvent être disponibles uniquement en anglais.
Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Canadian Guideline for Opioids for Chronic Non-Cancer Pain

Evidence, Guidelines and Recommendations

The Canadian Guideline for Opioid for Chronic Non-Cancer Pain was developed in response to concerns that Canadians are the second highest users per capita of opioids in the world, while the rates of opioid prescribing and opioid-related hospital visits and deaths have been increasing rapidly. The guideline's recommendations for clinical practice have been developed by an international team of clinicians, researchers and patients, led by the Michael G. DeGroote National Pain Centre at McMaster University and funded by Health Canada and the Canadian Institutes of Health Research. The guideline was published by the Canadian Medical Association Journal (CMAJ). The guideline incorporates medical evidence published since the previous national opioid use guideline was made available in 2017. They are recommendations for physicians, but are not regulatory requirements. The guideline does not look at opioid use for acute pain, nor for patients with pain due to cancer or in palliative care, or those under treatment for opioid use disorder or opioid addiction. Provided by Michael G. DeGroote National Pain Centre, McMaster University

Détails

Catégorie
Evidence, Guidelines and Recommendations
Format
Lien Web
Vues
0
Ajouté
25 août 2025
Tags
Psychiatrie
Douleur
Santé mentale
Troubles liés à l'usage de substances
Soins primaires
Médecine interne
Médecine d’urgence

Ressources connexes

Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline
The objective of this guideline is to provide clinical recommendations for the initiation, maintenance and discontinuation of buprenorphine/naloxone maintenance treatment in the ambulatory treatment of adults and adolescents with opioid dependence in Ontario.
Recommendations for the use of slow-release oral morphine as opioid agonist therapy
Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).
Safe Prescribing Practices for Addictive Medications and Management of Substance Use Disorders in Primary Care: A Pocket Reference for Primary Care Providers
Guidelines to Prescribing Addictive Medications developed by Women’s College Hospital for Primary Care Providers.

En savoir plus

Restez informé

Actualités et mises à jour directement dans votre boîte de réception.

© 2025 McMaster University et autres | 1280, rue Main Ouest | Hamilton, Ontario L8S 4L8 | Conditions d'utilisation